Biology and evolution of poorly differentiated neuroendocrine tumors (original) (raw)

• Perren, A. et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology http://dx.doi.org/10.1159/000457956 (2017).
• Ferrone, C.R. et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J. Clin. Oncol. 25, 5609–5615 (2007).
  Article PubMed Google Scholar
• Hochwald, S.N. et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J. Clin. Oncol. 20, 2633–2642 (2002).
  Article PubMed Google Scholar
• Liu, T.C., Hamilton, N., Hawkins, W., Gao, F. & Cao, D. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. Am. J. Surg. Pathol. 37, 853–859 (2013).
  Article PubMed PubMed Central Google Scholar
• Tang, L.H. et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin. Cancer Res. 22, 1011–1017 (2016).
  Article CAS PubMed Google Scholar
• den Bakker, M.A. & Thunnissen, F.B. Neuroendocrine tumours—challenges in the diagnosis and classification of pulmonary neuroendocrine tumours. J. Clin. Pathol. 66, 862–869 (2013).
  Article CAS PubMed Google Scholar
• Janson, E.T. et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 53, 1284–1297 (2014).
  Article PubMed Google Scholar
• Kidd, M., Modlin, I. & Öberg, K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat. Rev. Clin. Oncol. 13, 691–705 (2016).
  Article CAS PubMed Google Scholar
• Priemer, D.S. et al. Neuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 World Health Organization classification. Endocr. Pathol. 27, 123–135 (2016).
  Article CAS PubMed Google Scholar
• Reid, M.D., Balci, S., Saka, B. & Adsay, N.V. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr. Pathol. 25, 65–79 (2014).
  Article CAS PubMed Google Scholar
• Rouzbahman, M. & Clarke, B. Neuroendocrine tumors of the gynecologic tract: select topics. Semin. Diagn. Pathol. 30, 224–233 (2013).
  Article PubMed Google Scholar
• Scarpa, A. et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543, 65–71 (2017).
  Article CAS PubMed Google Scholar
• Mollaoglu, G. et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell 31, 270–285 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Fernandez-Cuesta, L. et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat. Commun. 5, 3518 (2014).
  Article PubMed CAS Google Scholar
• Rekhtman, N. et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin. Cancer Res. 22, 3618–3629 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Peifer, M. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104–1110 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298–305 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
• Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107–1120 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Rizvi, N.A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Tan, H.L. et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20, 890–903 (2014).
  Article CAS PubMed Google Scholar
• Feng, H., Shuda, M., Chang, Y. & Moore, P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096–1100 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Berman-Booty, L.D. & Knudsen, K.E. Models of neuroendocrine prostate cancer. Endocr. Relat. Cancer 22, R33–R49 (2015).
  Article CAS PubMed Google Scholar
• Zhou, Z. et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 66, 7889–7898 (2006).
  Article CAS PubMed Google Scholar
• Brodeur, G.M. & Castleberry, R.G. Neuroblastoma. in Principles and Practice of Pediatric Oncology (eds. Pizzo, P.A. & Poplack, D.G.) 739–767 (J.B. Lippincott Co., Philadelphia, PA, 1993).
  Google Scholar
• Shuda, M. et al. Merkel cell polyomavirus small T antigen induces cancer and embryonic merkel cell proliferation in a transgenic mouse model. PLoS One 10, e0142329 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Spurgeon, M.E., Cheng, J., Bronson, R.T., Lambert, P.F. & DeCaprio, J.A. Tumorigenic activity of merkel cell polyomavirus T antigens expressed in the stratified epithelium of mice. Cancer Res. 75, 1068–1079 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Verhaegen, M.E. et al. Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. J. Invest. Dermatol. 135, 1415–1424 (2015).
  Article CAS PubMed Google Scholar
• Cavallaro, U., Niedermeyer, J., Fuxa, M. & Christofori, G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat. Cell Biol. 3, 650–657 (2001).
  Article CAS PubMed Google Scholar
• Cui, M. et al. PTEN is a potent suppressor of small cell lung cancer. Mol. Cancer Res. 12, 654–659 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Kobayashi, S., Okada, S., Hasumi, T., Sato, N. & Fujimura, S. The significance of NSE and CEA as a differentiation marker for the cellular heterogeneity of small cell lung cancer. Tohoku J. Exp. Med. 189, 37–49 (1999).
  Article CAS PubMed Google Scholar
• McFadden, D.G. et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156, 1298–1311 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Meuwissen, R. et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4, 181–189 (2003).
  Article CAS PubMed Google Scholar
• Schaffer, B.E. et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 70, 3877–3883 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Shibayama, T. et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 32, 61–69 (2001).
  Article CAS PubMed Google Scholar
• Borromeo, M.D. et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep. 16, 1259–1272 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Gazdar, A.F. et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J. Thorac. Oncol. 10, 553–564 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• DeCaprio, J.A. et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54, 275–283 (1988).
  Article CAS PubMed Google Scholar
• Lane, D.P. & Crawford, L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261–263 (1979).
  Article CAS PubMed Google Scholar
• Linzer, D.I. & Levine, A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43–52 (1979).
  Article CAS PubMed Google Scholar
• Gingrich, J.R., Barrios, R.J., Foster, B.A. & Greenberg, N.M. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis. 2, 70–75 (1999).
  Article CAS PubMed Google Scholar
• Gingrich, J.R. et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56, 4096–4102 (1996).
  CAS PubMed Google Scholar
• Greenberg, N.M. et al. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92, 3439–3443 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Kaplan-Lefko, P.J. et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55, 219–237 (2003).
  Article PubMed Google Scholar
• Duan, W. et al. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. Oncogene 24, 1510–1524 (2005).
  Article CAS PubMed Google Scholar
• Gabril, M.Y. et al. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. Mol. Ther. 11, 348–362 (2005).
  Article CAS PubMed Google Scholar
• Gabril, M.Y. et al. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther. 9, 1589–1599 (2002).
  Article CAS PubMed Google Scholar
• Garabedian, E.M., Humphrey, P.A. & Gordon, J.I. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc. Natl. Acad. Sci. USA 95, 15382–15387 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Klezovitch, O. et al. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6, 185–195 (2004).
  Article CAS PubMed Google Scholar
• Kwabi-Addo, B. et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA 98, 11563–11568 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Masumori, N. et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 61, 2239–2249 (2001).
  CAS PubMed Google Scholar
• Perez-Stable, C. et al. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Lab. Invest. 74, 363–373 (1996).
  CAS PubMed Google Scholar
• Berman-Booty, L.D. et al. Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicol. Pathol. 43, 186–197 (2015).
  Article CAS PubMed Google Scholar
• Suttie, A.W. et al. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse. Toxicol. Pathol. 33, 386–397 (2005).
  Article CAS PubMed Google Scholar
• Tani, Y., Suttie, A., Flake, G.P., Nyska, A. & Maronpot, R.R. Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model. Vet. Pathol. 42, 306–314 (2005).
  Article CAS PubMed Google Scholar
• Ku, S.Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78–83 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Martin, P. et al. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am. J. Pathol. 179, 422–435 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84–88 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Brodeur, G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3, 203–216 (2003).
  Article CAS PubMed Google Scholar
• Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus, H.E. & Bishop, J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121–1124 (1984).
  Article CAS PubMed Google Scholar
• Kohl, N.E., Gee, C.E. & Alt, F.W. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 226, 1335–1337 (1984).
  Article CAS PubMed Google Scholar
• Althoff, K. et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene 34, 3357–3368 (2015).
  Article CAS PubMed Google Scholar
• Banerjee, S.A., Hoppe, P., Brilliant, M. & Chikaraishi, D.M. 5′ flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice. J. Neurosci. 12, 4460–4467 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Nakamura, T. et al. Deletions and rearrangements of the retinoblastoma gene in hepatocellular carcinoma, insulinoma and some neurogenic tumors as found in a study of 121 tumors. Jpn. J. Clin. Oncol. 21, 325–329 (1991).
  CAS PubMed Google Scholar
• The, I. et al. Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat. Genet. 3, 62–66 (1993).
  Article CAS PubMed Google Scholar
• Weiss, W.A., Aldape, K., Mohapatra, G., Feuerstein, B.G. & Bishop, J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985–2995 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Powers, J.T. et al. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. Nature 535, 246–251 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Dardenne, E. et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563–577 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, J.K. et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell 29, 536–547 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Huijbers, I.J. et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol. Med. 6, 212–225 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Rudin, C.M. & Poirier, J.T. MYC, MAX, and small cell lung cancer. Cancer Discov. 4, 273–274 (2014).
  Article CAS PubMed Google Scholar
• Sos, M.L. et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc. Natl. Acad. Sci. USA 109, 17034–17039 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Teicher, B.A. Targets in small cell lung cancer. Biochem. Pharmacol. 87, 211–219 (2014).
  Article CAS PubMed Google Scholar
• Wistuba, I.I., Gazdar, A.F. & Minna, J.D. Molecular genetics of small cell lung carcinoma. Semin. Oncol. 28 (Suppl. 4), 3–13 (2001).
  Article CAS PubMed Google Scholar
• Kim, D.W. et al. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer. Genes Dev. 30, 1289–1299 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Hofner, T. et al. Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer. J. Urol. 190, 2263–2270 (2013).
  Article CAS PubMed Google Scholar
• Kong-Beltran, M., Stamos, J. & Wickramasinghe, D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6, 75–84 (2004).
  Article CAS PubMed Google Scholar
• Byers, L.A. et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2, 798–811 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Aryee, M.J. et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med. 5, 169ra10 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487–495 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Jelinic, P. et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat. Genet. 46, 424–426 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Ramos, P. et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat. Genet. 46, 427–429 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Poirier, J.T. et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene 34, 5869–5878 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Pearse, A.G. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J. Histochem. Cytochem. 17, 303–313 (1969).
  Article CAS PubMed Google Scholar
• Fontaine, J. & Le Douarin, N.M. Analysis of endoderm formation in the avian blastoderm by the use of quail-chick chimaeras. The problem of the neurectodermal origin of the cells of the APUD series. J. Embryol. Exp. Morphol. 41, 209–222 (1977).
  CAS PubMed Google Scholar
• Rosai, J. The origin of neuroendocrine tumors and the neural crest saga. Mod. Pathol. 24 (Suppl. 2), S53–S57 (2011).
  Article CAS PubMed Google Scholar
• Yachida, S. et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am. J. Surg. Pathol. 36, 173–184 (2012).
  Article PubMed PubMed Central Google Scholar
• Brenner, B., Tang, L.H., Shia, J., Klimstra, D.S. & Kelsen, D.P. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin. Oncol. 34, 43–50 (2007).
  Article CAS PubMed Google Scholar
• Shia, J. et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am. J. Surg. Pathol. 32, 719–731 (2008).
  Article PubMed Google Scholar
• Oser, M.G., Niederst, M.J., Sequist, L.V. & Engelman, J.A. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 16, e165–e172 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Niederst, M.J. et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat. Commun. 6, 6377 (2015).
  Article CAS PubMed Google Scholar
• Sequist, L.V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
  Article PubMed PubMed Central Google Scholar
• Ohashi, K., Maruvka, Y.E., Michor, F. & Pao, W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31, 1070–1080 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104, 20932–20937 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Engelman, J.A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).
  Article CAS PubMed Google Scholar
• Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005).
  Article CAS PubMed Google Scholar
• Epstein, J.I. et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 38, 756–767 (2014).
  Article PubMed PubMed Central Google Scholar
• Lai, S.L. et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 15, 225–232 (1995).
  CAS PubMed Google Scholar
• Mertz, K.D. et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9, 200–206 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Burchardt, T. et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J. Urol. 162, 1800–1805 (1999).
  Article CAS PubMed Google Scholar
• Bang, Y.J. et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc. Natl. Acad. Sci. USA 91, 5330–5334 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Qiu, Y., Robinson, D., Pretlow, T.G. & Kung, H.J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA 95, 3644–3649 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Deng, X. et al. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res. 68, 9663–9670 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, D. et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74, 1272–1283 (2014).
  Article CAS PubMed Google Scholar
• True, L.D. et al. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am. J. Pathol. 161, 705–715 (2002).
  Article PubMed PubMed Central Google Scholar
• van Haaften Day, C. et al. Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma. Prostate 11, 271–279 (1987).
  Article CAS PubMed Google Scholar
• Pinthus, J.H. et al. WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Res. 60, 6563–6567 (2000).
  CAS PubMed Google Scholar
• Lapuk, A.V. et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J. Pathol. 227, 286–297 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Akamatsu, S. et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Reports 12, 922–936 (2015).
  Article CAS PubMed Google Scholar
• Aparicio, A. et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71, 846–856 (2011).
  Article CAS PubMed Google Scholar
• Noordzij, M.A. et al. Neuroendocrine differentiation in human prostatic tumor models. Am. J. Pathol. 149, 859–871 (1996).
  CAS PubMed PubMed Central Google Scholar
• Huss, W.J., Gregory, C.W. & Smith, G.J. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 60, 91–97 (2004).
  Article PubMed Google Scholar
• Chen, H. et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr. Relat. Cancer 19, 321–331 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kareta, M.S. et al. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell 16, 39–50 (2015).
  Article CAS PubMed Google Scholar
• Bishop, J.L. et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54–71 (2017).
  Article CAS PubMed Google Scholar
• Zou, M. et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-16-1174 (2017).
• Lynch, T.J. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046–2054 (2012).
  Article CAS PubMed Google Scholar
• Nghiem, P.T. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374, 2542–2552 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Khoo, K.H., Verma, C.S. & Lane, D.P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13, 217–236 (2014).
  Article CAS PubMed Google Scholar
• Mantovani, F., Walerych, D. & Sal, G.D. Targeting mutant p53 in cancer: a long road to precision therapy. FEBS J. 284, 837–850 (2017).
  Article CAS PubMed Google Scholar
• Brockmann, M. et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24, 75–89 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Gustafson, W.C. et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26, 414–427 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Hook, K.E. et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol. Cancer Ther. 11, 710–719 (2012).
  Article CAS PubMed Google Scholar
• Jahchan, N.S. et al. Identification and targeting of long-term tumor-propagating cells in small cell lung cancer. Cell Rep. 16, 644–656 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Baca, S.C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666–677 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).
  Article CAS PubMed Google Scholar
• Barbieri, C.E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685–689 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Biankin, A.V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015).
• Grasso, C.S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369–378 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Rudin, C.M. et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111–1116 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Taylor, B.S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Marshall, G.M. et al. The prenatal origins of cancer. Nat. Rev. Cancer 14, 277–289 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Zimmerman, K.A. et al. Differential expression of myc family genes during murine development. Nature 319, 780–783 (1986).
  Article CAS PubMed Google Scholar
• Yuan, J. & Yankner, B.A. Apoptosis in the nervous system. Nature 407, 802–809 (2000).
  Article CAS PubMed Google Scholar
• Kelly, K. & Balk, S.P. Reprogramming to resist. Science 355, 29–30 (2017).
  Article CAS PubMed Google Scholar